BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Sofinnova Raises €165M to Back European Biotech Startups

by BiopharmaTrend   •   March 19, 2025  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Bioeconomy & Society   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Sofinnova Partners, a European life sciences venture capital firm, has closed its Biovelocita II fund at €165 million, surpassing its original target. The fund attracted backing from major pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures. Biovelocita II marks an expansion of Sofinnova’s biotech acceleration strategy beyond Italy to include France, the United Kingdom, and Denmark, with plans to further extend across Europe.

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

Since its launch, the fund has screened over 300 projects and invested in several new biotech companies focused on therapeutic innovation. Among these are BioClec, which is working on therapies for Alzheimer’s disease; Forth Therapeutics, a University of Edinburgh spin-out developing precision treatments for fibrosis; and Signadori Bio, which is advancing a novel cell therapy platform based on research from the Gustave Roussy Institute.

Graziano Seghezzi, Managing Partner at Sofinnova Partners, highlighted that Biovelocita II builds on the success of Biovelocita I in Italy, reflecting strong interest from pharmaceutical partners and investors. Seghezzi noted that exceeding the fundraising target underscores demand for a strategic, pan-European approach to biotech acceleration.

Biovelocita team; Source: Sofinnova Partners

Biovelocita II is managed by partners Gabriella Camboni, Matthieu Coutet, Alex Leech, and Zhizhong Joel Yao. The fund is described as a major pan-European biotech accelerator, offering scientific founders management support, financial backing, and access to Sofinnova’s network and infrastructure. This model is designed to support the creation and scaling of biotech startups, combining expertise in biotech and medtech gained over more than a decade of startup acceleration.

Sofinnova Partners, founded in 1972, manages over €4 billion in assets and has backed more than 500 companies globally. The firm has a long track record of supporting early-stage and growth-stage biotech ventures, with offices in Paris, London, and Milan. The Biovelocita II fund strengthens Sofinnova’s position as a key player in European biotech funding and company creation.

Topics: Bioeconomy & Society   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.